We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Predictors of continuation for asenapine from real-world data in patients with schizophrenia.
- Authors
Takekita, Yoshiteru; Hiraoka, Shuichi; Iwama, Yasuhiro; Matsui, Daisuke; Aoki, Nobuatsu; Ogata, Haruhiko; Funatsuki, Toshiya; Shimizu, Toshiyuki; Murase, Yuji; Shimamoto, Yutaro; Koshikawa, Yosuke; Kato, Masaki
- Abstract
Background: The continuation rates of pharmacotherapy in schizophrenia exhibit variability, a phenomenon influenced by the specific antipsychotic agent prescribed and patient-related factors such as age and duration of illness. In this context, our study aims to elucidate the predictors of medication continuation for asenapine sublingual tablets, characterized by unique formulation properties. Methods: Our investigation leveraged real-world data collected through post-marketing surveillance in Japan, comprising 3236 cases. Utilizing multivariate logistic regression analysis, we identified patient-related factors associated with medication continuation as the primary outcome measure, subsequently employing survival analysis for further evaluation. Additionally, adverse event occurrence was assessed as a secondary outcome measure. Results: Multivariate logistic regression analysis unveiled significant predictors of asenapine continuation, notably including patient-related factors such as a chlorpromazine equivalent dose exceeding 600 mg/day and an illness duration of 25 years or more. While the overall continuation rate stood at 40.6%, patients exhibiting factors such as a chlorpromazine equivalent dose surpassing 600 mg/day or an illness duration exceeding 25 years demonstrated continuation rates of 46.3% and 47.9%, respectively. Remarkably, patients presenting both factors showcased the highest continuation rate at 52.5%. Conclusions: Our findings shed light on distinct patient-related predictors of asenapine continuation, deviating from those observed with other antipsychotic medications. This underscores the necessity of recognizing that predictive factors for antipsychotic medication continuation vary across different agents. Moving forward, elucidating these predictive factors for various antipsychotic medications holds paramount importance in schizophrenia treatment, facilitating the delivery of tailored therapeutic interventions for individual patients.
- Subjects
JAPAN; DRUG therapy for schizophrenia; PATIENT compliance; DRUG side effects; LOGISTIC regression analysis; ANTIPSYCHOTIC agents; SCHIZOPHRENIA; TREATMENT effectiveness; MULTIVARIATE analysis; DESCRIPTIVE statistics; DOSAGE forms of drugs; DRUGS; SURVIVAL analysis (Biometry); GENETIC techniques; EVALUATION
- Publication
Annals of General Psychiatry, 2024, Vol 23, Issue 1, p1
- ISSN
1744-859X
- Publication type
Article
- DOI
10.1186/s12991-024-00512-2